Back to Results

Daiichi Sankyo Co Ltd ADR (DSNKY)

Daiichi Sankyo Co Ltd ADR is a depositary receipt listed on OTC Markets that represents common stock of Daiichi Sankyo Company, Limited, a pharmaceutical company with operations in Japan, the United States, Europe, and other international markets. The underlying business develops, manufactures, and sells a broad range of prescription medicines spanning oncology, cardiovascular, diabetes, migraine, bone health, pain management, anemia, and infectious disease. Its portfolio includes products such as Enhertu, Turalio, Vanflyta, Injectafer, DATROWAY, Savaysa, Minnebro, Olmetec, Nilemdo, Nustendi, and Vimpat, among others. The company also markets vaccines for COVID-19, influenza, measles/rubella, mumps, and related infections. In addition, Daiichi Sankyo has a strategic collaboration with Lunit Inc. focused on biomarker discovery and translational research.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-DSNK.Y
$24.76
41.9% Upside
Undervalued
$22.95
31.5% Upside
Undervalued
Great
—
—
—
0.0%
July 31, 2026
19.2x
3.0x
2.4x
30.946 B
27.904 B
6.6%
100.0%
8.1
49.4%
-19.5%
Send a message
Valuation • Fair Value

Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$24.76

Estimated upside of 41.9% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$26.58

Discounted cash flow valuation reference.

Ben Graham Formula Value

$9.92

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$21.71

Earnings power value estimate.

Comps Fair Value

$23.76

Comparable-company valuation reference.

Analyst Price Target

$22.95

Analysts imply upside of 31.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

13.377 B

Current operating scale indicator.

Revenue Forecast

14.235 B

Forward revenue estimate.

EBITDA

1.827 B

Current operating profitability reference.

EBITDA Forecast

2.636 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.04

Intermediate zone that deserves monitoring.

Altman Z-Score

8.1

Relatively strong balance-sheet zone.

FCF / Net Income

-19.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 31, 2026

Days to Earnings

10

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

49.4%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) Stock Forecast & Technical Outlook

Review Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) Stock FAQ

Quick answers about Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$24.76
Estimated upside 41.9%
Valuation Rating
Undervalued
Estimated upside of 41.9%
Analyst Target
$22.95
Implied upside 31.5%
Financial Health
Great
Current financial-health read

The current fair value estimate for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is $24.76. This implies an estimated upside of 41.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 41.9% versus the current market price.

The available analyst price target for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is $22.95. The analyst target implies estimated upside of 31.5%.

The current financial health read for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is July 31, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is 19.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Daiichi Sankyo Co Ltd ADR is 30.946 B.

The current enterprise value listed for Daiichi Sankyo Co Ltd ADR is 27.904 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Daiichi Sankyo Co Ltd ADR is OTC-DSNK.Y, and the stock is listed on OTC Markets.

Daiichi Sankyo Co Ltd ADR (OTC-DSNK.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Daiichi Sankyo Co Ltd ADR is 6.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Daiichi Sankyo Co Ltd ADR is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)
Haw Par Corporation Ltd ADR (HAWPY) Haw Par Corporation Ltd ADR (HAWPY)